6-K 1 c107594.htm 6-K c107594.htm - Generated by SEC Publisher for SEC Filing

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549
 

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

November 30, 2012

________________

 

        NOVO NORDISK A/S        
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

logo.gif

 

13 November 2012

 

Trading in Novo Nordisk shares by board members, executives and associated persons on 12 November 2012

In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Please find below a statement of such trading in shares issued by Novo Nordisk.

 

Name

Kurt Anker Nielsen

Reason for reporting

Member of Board of Directors

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Sale of shares

Date of transaction

12 November 2012

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

3,300 shares

Total value of transaction

DKK 3,036,559

 

Definitions and background information:

Publication

Publication shall take place the day after Novo Nordisk receives sufficient information on the trading. Publication is only required when the total amount of transactions of a

 

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 2314

24 25 67 90

 

 

 

Company announcement No 75 / 2012

 

 


 

 

 

                                                                                                                                   Page 2 of 3

specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.

Who are board members, executives and associated persons?

Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)–3), or to which a board member/executive and/or a person mentioned in 1)–3) has managerial responsibilities or economic interests substantially equivalent to the legal person.

What is trading/transaction?

Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.

What is financial instrument and ID code?

Financial instrument includes shares listed on the NASDAQ OMX Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK006010261) of the Novo Nordisk share on the NASDAQ OMX Copenhagen or the code (NVO) on New York Stock Exchange.

What is date and place of transaction?

Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, ie NASDAQ OMX Copenhagen or New York Stock Exchange.

What is volume and value of transaction?

The volume of transaction is the number of shares (of DKK 1 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.  

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,900 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 2314

24 25 67 90

 

 

 

Company announcement No 75 / 2012

 

 


 

 

                                                                                                                                   Page 3 of 3

 

Further information

 

 

Media:

 

 

Anne Margrethe Hauge

+45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US)

+1 609 514 8316

kiau@novonordisk.com

 

 

Investors:

 

 

Kasper Roseeuw Poulsen

+45 4442 4303

krop@novonordisk.com

Frank Daniel Mersebach

+45 4442 0604

fdni@novonordisk.com

Lars Borup Jacobsen

+45 3075 3479

lbpj@novonordisk.com

Jannick Lindegaard (US)

+1 609 786 4575

jlis@novonordisk.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 2314

24 25 67 90

 

 

 

Company announcement No 75 / 2012

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: November 30, 2012

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer